T1	Non-query-able 0 175	Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study medication
T2	Drug 190 199	sorafenib
T3	Drug 203 214	oxaliplatin
T4	Procedure 221 233	chemotherapy
T5	Qualifier 190 220	sorafenib or oxaliplatin-based
R1	Has_qualifier Arg1:T4 Arg2:T5	
T6	Temporal 234 248	within 14 days
T7	Reference_point 252 282	first dose of study medication
R2	Has_index Arg1:T6 Arg2:T7	
R3	Has_temporal Arg1:T4 Arg2:T6	
T8	Condition 292 302;314 331	esophageal variceal bleeding
T9	Condition 306 331	gastric variceal bleeding
*	OR T8 T9
T10	Temporal 332 356	within the last 6 months
T11	Scope 292 331	esophageal or gastric variceal bleeding
R4	Has_temporal Arg1:T11 Arg2:T10	
T12	Condition 382 389	ascites
T13	Condition 419 439	portal vein invasion
T14	Qualifier 447 471	main portal branch (Vp4)
T15	Qualifier 473 491	inferior vena cava
T16	Condition 496 515	cardiac involvement
T17	Condition 519 522	HCC
T18	Procedure 532 539	imaging
T19	Scope 447 491	main portal branch (Vp4), inferior vena cava
*	OR T14 T15
R5	Has_scope Arg1:T13 Arg2:T19	
*	OR T13 T16
T20	Scope 419 515	portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement
R6	AND Arg1:T20 Arg2:T18	
R7	AND Arg1:T20 Arg2:T17	
T21	Condition 570 592	hepatic encephalopathy
T22	Temporal 593 613	in the last 6 months
R8	Has_temporal Arg1:T21 Arg2:T22	
T23	Procedure 640 662	hematologic transplant
T24	Procedure 625 636;652 662	solid organ transplant
*	OR T24 T23
T25	Procedure 678 694	systemic therapy
T26	Condition 699 702	HCC
R9	AND Arg1:T25 Arg2:T26	
T27	Drug 750 759	sorafenib
T28	Drug 763 774	oxaliplatin
T29	Procedure 781 793	chemotherapy
T30	Qualifier 750 780	sorafenib or oxaliplatin-based
R10	Has_qualifier Arg1:T29 Arg2:T30	
T31	Temporal 795 800	prior
T32	Reference_point 804 829	start of study medication
R11	Has_index Arg1:T31 Arg2:T32	
T33	Scope 678 793	systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy
R13	Has_temporal Arg1:T33 Arg2:T31	
T34	Temporal 838 844	active
T35	Condition 845 863	autoimmune disease
R14	Has_temporal Arg1:T35 Arg2:T34	
T36	Procedure 882 900	systemic treatment
T37	Temporal 901 920	in the past 2 years
R15	AND Arg1:T35 Arg2:T36	
R16	Has_temporal Arg1:T35 Arg2:T37	
T38	Not_a_criteria 922 989	Replacement therapy is not considered a form of systemic treatment.
T39	Condition 1010 1026	immunodeficiency
T40	Procedure 1043 1067	systemic steroid therapy
T41	Procedure 1089 1114	immunosuppressive therapy
T42	Temporal 1115 1134	within 7 days prior
T43	Reference_point 1138 1172	the first dose of study medication
R17	Has_index Arg1:T42 Arg2:T43	
*	OR T40 T41
T44	Scope 1043 1114	systemic steroid therapy or any other form of immunosuppressive therapy
R18	Has_temporal Arg1:T44 Arg2:T42	
*	OR T39 T44
T45	Procedure 1187 1207	locoregional therapy
T46	Procedure 1218 1256	transcatheter chemoembolization [TACE]
T47	Procedure 1258 1290	transcatheter embolization [TAE]
T48	Procedure 1292 1323	hepatic arterial infusion [HAI]
T49	Procedure 1325 1334	radiation
T50	Procedure 1336 1353	radioembolization
T51	Procedure 1358 1366	ablation
T52	Temporal 1382 1402	within 4 weeks prior
T53	Reference_point 1410 1440	first dose of study medication
R19	Has_index Arg1:T52 Arg2:T53	
T54	Qualifier 1211 1216	liver
T55	Qualifier 1371 1381	other site
*	OR T55 T54
R20	Has_qualifier Arg1:T45 Arg2:T54	
T56	Scope 1218 1366	transcatheter chemoembolization [TACE], transcatheter embolization [TAE], hepatic arterial infusion [HAI], radiation, radioembolization, or ablation
R21	Subsumes Arg1:T45 Arg2:T56	
R22	Has_temporal Arg1:T45 Arg2:T52	
T57	Procedure 1450 1463	major surgery
T58	Qualifier 1467 1472	liver
T59	Qualifier 1476 1486	other site
*	OR T58 T59
R23	Has_qualifier Arg1:T57 Arg2:T58	
T60	Temporal 1487 1507	within 4 weeks prior
T61	Reference_point 1515 1545	first dose of study medication
R24	Has_index Arg1:T60 Arg2:T61	
R25	Has_temporal Arg1:T57 Arg2:T60	
T62	Procedure 1557 1570	minor surgery
T63	Temporal 1571 1584	≤7 days prior
T64	Reference_point 1592 1622	first dose of study medication
R26	Has_index Arg1:T63 Arg2:T64	
R27	Has_temporal Arg1:T62 Arg2:T63	
T65	Undefined_semantics 1624 1763	Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start
T66	Context_Error 1624 1763	Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start
T67	Subjective_judgement 1632 1652	recovered adequately
T68	Condition 1792 1802	malignancy
T69	Qualifier 1781 1791	additional
R28	Has_qualifier Arg1:T68 Arg2:T69	
T70	Temporal 1803 1857	within 3 years prior to first dose of study medication
T71	Reference_point 1827 1857	first dose of study medication
T72	Procedure 1891 1898	treated
T73	Qualifier 1880 1890	curatively
R29	Has_qualifier Arg1:T72 Arg2:T73	
T74	Undefined_semantics 1880 1898	curatively treated
T75	Condition 1899 1931	basal cell carcinoma of the skin
T76	Condition 1933 1968	squamous cell carcinoma of the skin
*	OR T75 T76 T77
T77	Condition 1996 2011	in situ cancers
T78	Procedure 1987 1995	resected
T79	Qualifier 1976 1986	curatively
R30	Has_qualifier Arg1:T78 Arg2:T79	
T80	Qualifier 1880 1898	curatively treated
R31	Has_qualifier Arg1:T75 Arg2:T80	
T81	Qualifier 1976 1995	curatively resected
R32	Has_qualifier Arg1:T77 Arg2:T81	
T82	Scope 1880 2011	curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers
R34	Has_index Arg1:T70 Arg2:T71	
R35	Has_temporal Arg1:T68 Arg2:T70	
T83	Observation 2025 2032	history
T84	Observation 2044 2052	evidence
T85	Condition 2057 2096	central nervous system (CNS) metastases
T86	Condition 2104 2128	carcinomatous meningitis
*	OR T86 T85
T87	Scope 2057 2128	central nervous system (CNS) metastases and/or carcinomatous meningitis
R36	Has_context Arg1:T87 Arg2:T84	
R37	Has_temporal Arg1:T87 Arg2:T83	
T89	Drug 2190 2198	steroids
T90	Drug 2210 2221	pneumonitis
T91	Temporal 2202 2209	current
T92	Observation 2136 2143	history
T93	Condition 2148 2175	non-infectious) pneumonitis
R38	AND Arg1:T93 Arg2:T89	
*	OR T89 T90
R39	Has_temporal Arg1:T90 Arg2:T91	
R40	Has_temporal Arg1:T93 Arg2:T92	
T88	Procedure 2257 2273	systemic therapy
T94	Temporal 2230 2236	active
T95	Condition 2237 2246	infection
T96	Qualifier 2247 2273	requiring systemic therapy
R41	Has_qualifier Arg1:T95 Arg2:T96	
R42	Has_temporal Arg1:T95 Arg2:T94	
T99	Procedure 2502 2515	immunotherapy
T100	Drug 2524 2568	anti-Programmed Cell Death Receptor 1 (PD-1)
T101	Drug 2570 2622	Programmed Cell Death Receptor Ligand 1 (anti-PD-L1)
T102	Drug 2627 2680	anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)
T103	Non-query-able 2699 2750	participated in clinical studies with pembrolizumab
T104	Drug 2737 2750	pembrolizumab
*	OR T100 T101 T102
T105	Scope 2524 2680	anti-Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)
R43	Has_scope Arg1:T99 Arg2:T105	
T106	Observation 2699 2750	participated in clinical studies with pembrolizumab
*	OR T99 T106
T107	Condition 2775 2809	human immunodeficiency virus (HIV)
T108	Observation 2764 2771	history
R44	Has_temporal Arg1:T107 Arg2:T108	
T109	Condition 2832 2843	Hepatitis B
T110	Qualifier 2815 2824	untreated
T111	Qualifier 2825 2831	active
R45	Has_qualifier Arg1:T109 Arg2:T111	
R46	Has_qualifier Arg1:T109 Arg2:T110	
T112	Condition 2849 2860	hepatitis C
T113	Procedure 2892 2907	therapy for HCV
T114	Temporal 2908 2922	<4 weeks prior
T115	Drug 2936 2949	pembrolizumab
T116	Reference_point 2926 2949	receiving pembrolizumab
R47	Has_index Arg1:T114 Arg2:T116	
R48	Has_temporal Arg1:T113 Arg2:T114	
R49	AND Arg1:T112 Arg2:T113	
T117	Condition 2966 2978	live vaccine
T118	Temporal 2986 2999	30 days prior
T119	Reference_point 3007 3034	first dose of study therapy
R50	Has_index Arg1:T118 Arg2:T119	
R51	Has_temporal Arg1:T117 Arg2:T118	
T120	Negation 1858 1879	with the exception of
R33	Has_negation Arg1:T82 Arg2:T120	
R52	Has_scope Arg1:T68 Arg2:T82	
T97	Condition 2278 2286	pregnant
T98	Observation 2290 2304	breast feeding
*	OR T97 T98 T121 T122
T121	Observation 2308 2329	expecting to conceive
T122	Observation 2308 2320;2333 2339	expecting to father
T123	Temporal 2340 2388	starting from the first dose of study medication
T124	Reference_point 2354 2388	the first dose of study medication
R53	Has_index Arg1:T123 Arg2:T124	
T125	Temporal 2390 2417	throughout the study period
T126	Reference_point 2401 2417	the study period
R55	Has_index Arg1:T125 Arg2:T126	
T127	Temporal 2423 2481	for up to 120 days after the last dose of study medication
T128	Reference_point 2448 2481	the last dose of study medication
R56	Has_index Arg1:T127 Arg2:T128	
T129	Scope 2340 2481	starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication
R54	Has_scope Arg1:T122 Arg2:T129	
T130	Negation 739 749	other than
R12	Has_negation Arg1:T29 Arg2:T130	
R57	AND Arg1:T25 Arg2:T29	
